The report highlights Alnylam's commitment to ethical and responsible business practices, focusing on their progress in patient access, health equity, employee engagement, and environmental sustainability. Key highlights include the launch of their fifth product in four years, the expansion of their Alnylam Challengers program to support refugees in Europe, and the implementation of a new supplier diversity program. Alnylam continues to demonstrate their dedication to research and development, with the presentation of clinical results for ongoing clinical trials and the publication of new scientific findings. The company also focuses on improving environmental performance and sustainability by reducing greenhouse gas emissions and decreasing water consumption. Alnylam is committed to creating a diverse and inclusive workplace culture and continues to provide opportunities for professional development and growth.
Go back to company
Alnylam Pharmaceuticals Inc 2022 Corporate Responsibility Report
Issuing Company Alnylam Pharmaceuticals Inc.
Report Type Sustainability Report
Report Language EN
Report Filesize 12.72 MB
No. of Pages 62 pages
Reporting period2022
Report EditionUnknown
Assurance Provider Unknown
Reporting Standards GRI; SASB
Materiality Assessmenttrue